Jane Street’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jane Street’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.33M	Buy	274,000 +181,500	+196%	+$3.29M	﹤0.01%	3621
2026 Q1	$1.72M	Buy	92,500 +53,500	+137%	+$886K	﹤0.01%	5376
2025 Q4	$514K	Sell	39,000 -773,700	-95%	-$9.13M	﹤0.01%	7624
2025 Q3	$5.83M	Buy	812,700 +737,600	+982%	+$38.4M	﹤0.01%	3198
2025 Q2	$3.54M	Sell	75,100 -15,700	-17%	-$640K	﹤0.01%	3492
2025 Q1	$3.55M	Buy	90,800 +78,700	+650%	+$3.39M	﹤0.01%	3455
2024 Q4	$655K	Buy	+12,100	New	+$618K	﹤0.01%	6188
2024 Q3	–	Sell	-14,700	Closed	-$646K	–	10098
2024 Q2	$646K	Sell	14,700 -2,300	-14%	-$97.4K	﹤0.01%	6599
2024 Q1	$854K	Buy	17,000 +11,000	+183%	+$597K	﹤0.01%	5698
2023 Q4	$362K	Sell	6,000 -8,500	-59%	-$438K	﹤0.01%	7328
2023 Q3	$827K	Buy	+14,500	New	+$800K	﹤0.01%	5482

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street's MLTX Position: Q2 2026 in Review

Jane Street increased its MoonLake Immunotherapeutics (MLTX) stake by 88% in Q2 2026, buying an estimated $7.25M and bringing the position to 853,386 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Jane Street first reported a position in MLTX in Q1 2022 and has held it in 13 quarters since. The position peaked at $22.2M in Q4 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Jane Street held 853,386 shares of MoonLake Immunotherapeutics worth $16.6M as of Q2 2026.
Jane Street bought 399,761 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $7.25M.
MoonLake Immunotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #2322 holding.
Jane Street first reported a position in MoonLake Immunotherapeutics in Q1 2022 and has held it in 13 quarters since.
Jane Street's MoonLake Immunotherapeutics position peaked at $22.2M in Q4 2025.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.